Top Heal Care Stocks To Own For 2021

Coronary Heart Disease is the number one killer of adults in the United States. Heart attacks strike more than 1,000,000 Americans each year. A heart attack occurs when one of the blood vessels supplying a person’s heart muscle is closed off by atherosclerotic plaque. The starved muscle dies within minutes. This leaves a scar that cannot contribute its share to the function of the heart. Heart attacks involving the front of the heart tend to be larger, causing more muscle damage, and often lead to chronic heart failure. That is, if the patient survives the initial heart attack. In contrast, heart attacks involving the inferior wall of the heart are smaller and less risky.

Center for Disease Control (CDC) statistics show that there are roughly 200,000 hospital admissions each year for patients suffering from pulmonary hypertension. The median survival rate after diagnosis of primary pulmonary hypertension is less than 3 years. However, patients who do not develop right heart failure may survive for more than 10 years. This is why VentriPoint Diagnostics Ltd. (OTCBB: VPTDF) has developed its VMSTM heart analysis system. “The VMSTM will enable us to better image the hearts of patients at risk for pulmonary hypertension and is a wonderful alternative to MRI.” – The Cleveland Clinic

Previously the VMSTM was limited in use on adults with known Pulmonary Arterial Hypertension (PAH) which is newly diagnosed in approximately 200,000 individuals each year in the USA. Now the VMSTM can be used to help diagnose the more than 20,000,000 people in the U.S. who suffer from heart disease. “I expect that an assessment of RV volume and function using the VMSTM will become part of the routine clinical ultrasound evaluation for patients at risk for PAH. A simple way to detect and monitor PAH is gravely needed and this methodology will be extremely useful to quantify interventions (therapeutic and surgical) performed on the right ventricle,” stated Roberto M. Lang, M.D.., is an internationally renowned cardiologist and specialist in echocardiography at the University of Chicago and is the Past President of the American Society of Echocardiography.

Top Heal Care Stocks To Own For 2021: Avino Silver(ASM)

In Canada, an issuer is required to provide technical information with respect to mineralization, including reserves and resources, if any, on its mineral exploration properties in accordance with Canadian requirements, which differ significantly from the requirements of the SEC applicable to registration statements and reports filed by United States companies pursuant to the Securities Act, or the Exchange Act. As such, information contained in this annual report concerning descriptions of mineralization under Canadian standards may not be comparable to similar information made public by United States companies subject to the reporting and disclosure requirements of the SEC. In particular, this annual report on Form 20-F includes the terms “mineral resource,” “measured mineral resource,” “indicated mineral resource” and “inferred mineral resource”.   Advisors’ Opinion:

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Avino Silver & Gold Mines (ASM)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Bard Associates Inc. increased its position in shares of Avino Silver & Gold Mines Ltd (NYSEAMERICAN:ASM) by 41.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,595,700 shares of the basic materials company’s stock after buying an additional 466,250 shares during the period. Bard Associates Inc. owned 3.02% of Avino Silver & Gold Mines worth $1,979,000 at the end of the most recent reporting period.

Top Heal Care Stocks To Own For 2021: Ohr Pharmaceuticals, Inc.(OHRP)

OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is OHR-102 eye drops, a novel therapeutic product, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating OHR-102 eye drops, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, retinal vein occlusion, and proliferative diabetic retinopathy. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as steroid induced glaucoma, allergies, and retinal disease. OHR Pharmaceutical, Inc. is headquartered in New York, New York.

Advisors’ Opinion:

  • [By Max Byerly]

    Get a free copy of the Zacks research report on OHR Pharmaceutical (OHRP)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    OHR Pharmaceutical Inc (NASDAQ:OHRP)’s share price fell 9.1% during trading on Tuesday . The stock traded as low as $0.22 and last traded at $0.24. 16,800 shares were traded during trading, a decline of 98% from the average session volume of 1,040,668 shares. The stock had previously closed at $0.22.

  • [By Shane Hupp]

    OHR Pharmaceutical Inc (NASDAQ:OHRP)’s share price hit a new 52-week high and low on Thursday . The company traded as low as $0.18 and last traded at $0.19, with a volume of 5632 shares traded. The stock had previously closed at $0.19.

  • [By Paul Ausick]

    Ohr Pharmaceuticals Inc. (NASDAQ: OHRP) dropped nearly 13% Tuesday to post a new 52-week low of $0.24. Shares closed at $0.27 on Friday and the stock’s 52-week high is $2.18. Volume was around 1 million, about a third of the daily average of about 3.3 million. The company had no specific news Tuesday.

Top Heal Care Stocks To Own For 2021: MEDIFAST INC(MED)

Medifast, Inc., through its subsidiaries, engages in the production, distribution, and sale of weight management and disease management products, and other consumable health and diet products in the United States. The company?s product lines include weight and disease management, meal replacement, and vitamins. It also operates weight control centers that offer Medifast programs for weight loss and maintenance, customized patient counseling, and inbody composition analysis. The company markets its products under the Medifast and Essential brand names, including shakes, appetite suppression shakes, women?s health shakes, diabetics shakes, joint health shakes, coronary health shakes, calorie burn drinks, calorie burn flavor infusers, antioxidant shakes, antioxidant flavor infusers, bars, crunch bars, soups, chili, oatmeal, pudding, scrambled eggs, hot cocoa, cappuccino, chai latte, iced teas, fruit drinks, pretzels, puffs, brownie, pancakes, soy crisps, crackers, and omega 3 and digestive health products. Medifast Inc. sells its products through various channels of distribution comprising Web, call center, independent health advisors, medical professionals, weight loss clinics, and direct consumer marketing supported via the phone and the Web; Take Shape for Life, a physician led network of independent health coaches; and weight control centers. The company was founded in 1980 and is headquartered in Owings Mills, Maryland.

Advisors’ Opinion:

  • [By Motley Fool Transcribers]

    Medifast Inc (NYSE:MED)Q42018 Earnings Conference CallFeb. 26, 2019, 4:30 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Logan Wallace]

    MediBloc [MED] (CURRENCY:MED) traded 11.7% lower against the U.S. dollar during the 1 day period ending at 20:00 PM ET on February 16th. MediBloc [MED] has a total market capitalization of $19.63 million and $281,103.00 worth of MediBloc [MED] was traded on exchanges in the last 24 hours. During the last seven days, MediBloc [MED] has traded down 27.6% against the U.S. dollar. One MediBloc [MED] token can currently be bought for $0.0066 or 0.00000100 BTC on major exchanges including Coinrail, Bibox and Gate.io.

Top Heal Care Stocks To Own For 2021: CareDx, Inc.(CDNA)

CareDx, Inc., a molecular diagnostics company, focuses on the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients in the United States and internationally. The companys commercialized testing solution includes the AlloMap heart transplant molecular test (AlloMap), a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection. It is also developing AlloSure, a next-generation sequencing-based test to detect donor-derived cell-free DNA after transplantation. The company markets its AlloMap solution to healthcare providers through its direct sales force that targets transplant centers and their physicians, coordinators, and nurse practitioners. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.

Advisors’ Opinion:

  • [By Cory Renauer]

    Shares of CareDx (NASDAQ:CDNA),a specialized diagnostics company, jumped 16% during morningtrading in response to the company’s fourth-quarter earnings report. Investors pleased to see continued profitability have driven the stock 9.7% higher as of 3:29 p.m. EST on Thursday.

  • [By Motley Fool Transcribers]

    CareDx Inc (NASDAQ:CDNA)Q42018 Earnings Conference CallMarch 06, 2019, 4:30 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Leave a Reply

Your email address will not be published. Required fields are marked *